HSBC cut shares of Shire PLC (LON:SHP) to a hold rating in a report released on Monday morning. They currently have GBX 5,250 ($68.53) target price on the biopharmaceutical company’s stock, down from their prior target price of GBX 5,400 ($70.49).
Other equities research analysts also recently issued research reports about the company. Deutsche Bank AG reiterated a buy rating and set a GBX 5,600 ($73.10) price objective on shares of Shire PLC in a research report on Monday, June 13th. Royal Bank Of Canada reiterated an outperform rating on shares of Shire PLC in a research report on Friday, July 22nd. JPMorgan Chase & Co. reiterated an overweight rating and set a GBX 6,300 ($82.23) price objective on shares of Shire PLC in a research report on Tuesday, August 16th. Jefferies Group increased their price objective on Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the company a buy rating in a research report on Wednesday, August 3rd. Finally, Citigroup Inc. reiterated a buy rating on shares of Shire PLC in a research report on Wednesday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Shire PLC currently has a consensus rating of Buy and an average target price of GBX 5,828 ($76.07).
Shares of Shire PLC (LON:SHP) opened at 5108.00 on Monday. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00. The company’s market capitalization is GBX 34.88 billion. The stock has a 50 day moving average of GBX 4,990.28 and a 200-day moving average of GBX 4,501.92.
The firm also recently announced a dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 8th will be given a dividend of GBX 3.51 ($0.05) per share. This represents a yield of 0.07%. The ex-dividend date is Thursday, September 8th.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.